Drug
sodium selenite
sodium selenite is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
2
33%
Ph phase_1
3
50%
Ph phase_2
1
17%
Phase Distribution
3
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
2(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(3)
Terminated(1)
Other(2)
Detailed Status
Completed3
unknown2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 13 (50.0%)
Phase 21 (16.7%)
Phase 32 (33.3%)
Trials by Status
unknown233%
completed350%
withdrawn117%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_1
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
NCT02184533
withdrawnphase_1
Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone
NCT04296578
unknownphase_3
SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial).
NCT02002247
unknownphase_1
Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma
NCT01959438
completedphase_3
Selenium in the Treatment of Arsenic Toxicity and Cancers
NCT01442727
Clinical Trials (6)
Showing 6 of 6 trials
NCT02184533Phase 1
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
NCT04296578Phase 1
Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone
NCT02002247Phase 3
SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial).
NCT01959438Phase 1
Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma
NCT01442727Phase 3
Selenium in the Treatment of Arsenic Toxicity and Cancers
NCT00188604Phase 2
The Use of Selenium to Treat Secondary Lymphedema - Breast Cancer
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6